MARKET

HSTO

HSTO

Histogen Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.1788
-0.0042
-2.30%
After Hours: 0.1789 +0.0001 +0.06% 17:15 05/24 EDT
OPEN
0.1856
PREV CLOSE
0.1830
HIGH
0.1882
LOW
0.1771
VOLUME
1.03M
TURNOVER
0
52 WEEK HIGH
1.230
52 WEEK LOW
0.1500
MARKET CAP
8.93M
P/E (TTM)
-0.4470
1D
5D
1M
3M
1Y
5Y
Histogen to Present at the H.C. Wainwright Global Investment Conference
SAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective inhibitors focused on treatments for infectious and in...
GlobeNewswire · 05/17 20:05
Recap: Histogen Q1 Earnings
Histogen (NASDAQ:HSTO) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Histogen beat estimated earnings by 85.71%, reporting an EPS of $-0.01 versus an estimate of ...
Benzinga · 05/12 22:36
Histogen Q1 EPS $(0.01) Beats $(0.07) Estimate
Histogen (NASDAQ:HSTO) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.07) by 85.71 percent. This is a 92.86 percent increase over losses of $(0.14) per share from the same
Benzinga · 05/12 21:13
Histogen GAAP EPS of -$0.01, revenue of $3.7M
Histogen press release (NASDAQ:HSTO): Q1 GAAP EPS of -$0.01. Revenue of $3.7M (+760.5% Y/Y).
Seekingalpha · 05/12 20:26
-- Earnings Flash (HSTO) HISTOGEN Reports Q1 Revenue $3.8M
MT Newswires · 05/12 16:39
Histogen to Report First Quarter 2022 Financial Results and Provide Business Update
SAN DIEGO, April 28, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective inhibitors focused on treatments for infectious and ...
GlobeNewswire · 04/28 20:05
51 Biggest Movers From Thursday
Gainers MedAvail Holdings, Inc. (NASDAQ: MDVL) shares surged 69.4% to close at $2.44 on Thursday. Ally Bridge Group recently reported a purchase of 21.176 million shares of MedAvail Holdings for an average price of $1.06 per share.
Benzinga · 04/18 09:21
Top Premarket Decliners
MT Newswires · 04/13 08:03
More
No Data
Learn about the latest financial forecast of HSTO. Analyze the recent business situations of Histogen Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

50.00%Strong Buy
50.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average HSTO stock price target is 2.250 with a high estimate of 3.000 and a low estimate of 1.500.
High3.000
Average2.250
Low1.500
Current 0.1788
EPS
Actual
Estimate
-0.14-0.10-0.07-0.03
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 53
Institutional Holdings: 5.00M
% Owned: 10.01%
Shares Outstanding: 49.95M
TypeInstitutionsShares
Increased
7
633.26K
New
4
159.28K
Decreased
4
64.41K
Sold Out
6
5.03M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.05%
Pharmaceuticals & Medical Research
+0.25%
Key Executives
Chairman/President/Chief Executive Officer/Executive Director
Steven Mento
Founder/Chief Scientific Officer
Gail Naughton
Chief Financial Officer/Executive Vice President/Secretary
Susan Knudson
Executive Vice President
Moya Daniels
Lead Director/Independent Director
David Crean
Independent Director
Rochelle Fuhrmann
Independent Director
Jonathan Jackson
Independent Director
Daniel Kisner
Independent Director
Brian Satz
Independent Director
Susan Windham-bannister
No Data
No Data
About HSTO
Histogen Inc. is a clinical-stage therapeutics company. The Company is focused on developing restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function. It has a portfolio of product candidates derived from one core technology process that utilizes proteins and growth factors produced by hypoxia-induced multipotent cells, without using embryonic stem cells or animal components. The Company's product pipelines include CCM Cosmetics, HST 003, HST 004, and Emricasan. HST 003 is a human extracellular matrix (hECM), a naturally secreted material, which is used for treatment of joint cartilage repair. HST 004 is a cell conditioned medium (CCM) solution, which is used for treatment of spinal disc repair. Emricasan is an orally active pan-caspase inhibitor being jointly developed with its partner Amerimmune for the treatment of COVID-19.

Webull offers kinds of Histogen Inc stock information, including NASDAQ:HSTO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HSTO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HSTO stock methods without spending real money on the virtual paper trading platform.